News & Updates
MNG is excited to announce the launch of 15 new next-generation sequencing (NGS) panels. In an effort to meet the needs of our clients, we are introducing a Comprehensive Hearing Loss panel and a Comprehensive Vision Loss & Eye Disorders panel, both including mtDNA analysis.
Due to a manufacturer reagent change, MNG will discontinue testing for Folate Receptor Antibodies.
Succinic semialdehyde dehydrogenase (SSADH) deficiency is a disorder affecting GABA metabolism. This disorder is generally diagnosed by the finding of elevated levels of gamma hydroxybutyric acid (GHB) in urine using standard organic acid analysis.
MNG is driven to help our healthcare partners, patients, and families find the answers they need when it comes to a diagnosis. MNG has solutions allowing economical reflex options to further investigate negative or inconclusive results.
The most common mutation, seen in >95% of Friedreich ataxia (FRDA) patients, is a GAA triplet-repeat expansion in intron 1 of the FXN gene. Individuals with less than 500 repeats often have a later age of onset compared to patients with greater than 600 repeats.
Recent studies have suggested a connection between mitochondrial DNA (mtDNA) and autism. At MNG Laboratories™, we strive to offer a comprehensive portfolio of tests to provide your patients with the answers they need.
MNG Laboratories, an Atlanta-based neurogenetic testing company, is pleased to announce that it has signed a Distribution Agreement with Pronto Diagnostics, a leading Israeli genomics company, to exclusively market its complete line of Clinical RNA Sequencing Services in Israel.
MNG Laboratories is pleased to announce the signing of several key international distributor agreements in Asia, Latin America and Eastern Europe.
We are pleased to announce that we have made substantial improvements in our ability to search for and identify the known pathogenic variants likely to cause dystonia.